Efficacy of Metformin for Sputum Conversion in Patients With Active Pulmonary Tuberculosis

• Status: Recruiting
• Trial end date: 2023-03-31
• Target enrollment: 0
• Participant gender: All

Summary

This study was a randomized controlled trial studying about acid-fast bacillus sputum conversion ratio from positive to negative of pulmonary tuberculosis patients between metformin with pulmonary tuberculosis standard treatment group and placebo drug with pulmonary tuberculosis standard treatment.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mahidol University
• Collaborator: Ministry of Health, Thailand
• Treatments: Metformin

Criteria

Inclusion Criteria:

• Age more than 18 years old

• Be diagnosed pulmonary tuberculosis compatible with clinical and chest x ray by an internist

• Presence of at least one acid -fast bacillus in the sputum

• Recieve pulmonary tuberculosis standard treatment compose of isoniazid, rifampicin, pyrazinamide and ethambutol

• BMI more than 18.5 kg/m2

• Reserach participants were diagnosed diabetes or non diabetes.

• Research participants or representatives are welcome to join the project by signing.

Exclusion Criteria:

• Pregnancy

• Organ transplants

• eGFR less than 45 ml/min/1.73 m2

• AST, ALT or total bilirubin more than three times

• Researh participants have received metformin at least 2 weeks before joining the project.

• Immunocompromised host such as patient receive systemic immunosuppressive drugs or systemic chemotherapy.

• Research participant or his representative refuses or requests to withdraw,